Viral Entry and Vaccines

Focusing on the COVID-19 virus (SARS-CoV-2), hepatitis C, and other significant viruses, we study how viruses enter cells and how the immune system can block infection. Using structural biology, immunology, and vaccine design, we develop strategies to prevent viral infection. This includes creating next-generation vaccines and understanding protective immune responses.

Our research focuses on understanding the molecular mechanisms of viral entry and the immune responses that can prevent infection. To inform the rational design of vaccines, we use a multidisciplinary approach combining:

• structural biology
• virology
• protein engineering
• systems immunology.

A major focus of our work is hepatitis C virus (HCV), one of the most genetically diverse viruses, and SARS-CoV-2, the virus responsible for COVID-19. Both pathogens pose significant challenges for vaccine development due to their ability to evade immune recognition.

By investigating how antibodies and T cells respond to infection or vaccination, we aim to define the key features of protective immunity. This knowledge guides the development of next-generation vaccines capable of inducing broad and durable protection.

Our vaccine candidates are tested in preclinical models to evaluate safety and immunogenicity. The goal is to progress to human clinical trials for real-world impact against these and other emerging viral threats.